Background Endometrial cancer poses a serious threat to women’s health worldwide, and its pathogenesis, although actively explored, is not fully understood. DLGAP5 is a recently identified cell cycle-regulation gene not reported in endometrial cancer. This study was aiming to analyze the role of DLGAP5 in tumorigenesis and development and to investigate its prognostic significance of patients with endometrial cancer. Methodology Microarray datasets (GSE17025, GSE39099 and GSE63678) from the GEO database were used for comparative analysis, and their intersection was obtained by applying the Venn diagram, and DLGAP5 was selected as the target gene. Next, transcriptome data (n = 578) was downloaded from TCGA-UCEC to analyze the mRNA expression profile of DLGAP5. Then, immunohistochemical data provided by HPA were used to identify the different protein expression levels of DLGAP5 in tumor tissues and normal tissues. Subsequently, the prognostic meaning of DLGAP5 in patients with endometrial cancer was explored based on survival data from TCGA-UCEC (n = 541). Finally, the reliability of DLGAP5 expression was verified by RT-qPCR. Results Transcriptome data from TCGA-UCEC, immunohistochemical data from HPA, and RT-qPCR results from clinical samples were used for triple validation to confirm that the expression of DLGAP5 in endometrial cancer tissues was significantly higher than that in normal endometrial tissues. Kaplan–Meier survival analysis announced that the expression level of DLGAP5 was negatively correlated with the overall survival of patients with endometrial cancer. Conclusions DLGAP5 is a potential oncogene with cell cycle regulation, and its overexpression can predict the poor prognosis of patients with endometrial cancer. As a candidate target for the diagnosis and treatment of endometrial cancer, it is worthwhile to make further study to reveal the carcinogenicity of DLGAP5 and the mechanism of its resistance of organisms.

中文翻译：

---

DLGAP5在子宫内膜癌中的鉴定及预后价值

背景子宫内膜癌对世界范围内的女性健康构成严重威胁，其发病机制虽然被积极探索，但尚未完全了解。DLGAP5 是最近发现的一种在子宫内膜癌中未见报道的细胞周期调节基因。本研究旨在分析DLGAP5在肿瘤发生和发展中的作用，并探讨其对子宫内膜癌患者的预后意义。Methodology 使用GEO数据库中的微阵列数据集（GSE17025、GSE39099和GSE63678）进行比较分析，应用维恩图得到它们的交集，并选择DLGAP5作为靶基因。接下来，从 TCGA-UCEC 下载转录组数据 (n = 578) 以分析 DLGAP5 的 mRNA 表达谱。然后，HPA 提供的免疫组化数据用于鉴定 DLGAP5 在肿瘤组织和正常组织中的不同蛋白表达水平。随后，根据 TCGA-UCEC (n = 541) 的生存数据探讨了 DLGAP5 在子宫内膜癌患者中的预后意义。最后，通过 RT-qPCR 验证了 DLGAP5 表达的可靠性。结果TCGA-UCEC的转录组数据、HPA的免疫组化数据和临床样本的RT-qPCR结果用于三重验证，证实DLGAP5在子宫内膜癌组织中的表达明显高于正常子宫内膜组织。Kaplan-Meier 生存分析表明，DLGAP5 的表达水平与子宫内膜癌患者的总生存期呈负相关。结论 DLGAP5是一种具有细胞周期调控的潜在癌基因，其过表达可预测子宫内膜癌患者的不良预后。作为子宫内膜癌诊治的候选靶点，DLGAP5的致癌性及其生物体耐药机制值得进一步研究。